The overall purpose of this observational Post Market Clinical Follow Up (PMCF) study is to ensure continued acceptability of the benefit risk ratio by assessment of safety and performance, in patients undergoing cardiovascular repair or reconstruction surgery under standard clinical care with the commercially available Glycar Pericardial Patch.
To comply with Medical Device Regulation (MDR) Post Market Clinical Follow Up (PMCF) requirements through proactive ongoing assessment of the safety, efficacy, and performance of the commercially available Glycar Pericardial Patch in patients undergoing cardiovascular repair or reconstruction surgery. This real-world evidence retrospective data collection single-arm multicentre, observational, non-interventional study will enrol up to a minimum of 50 consecutive participants who meet inclusion criteria, in 2-3 centres. The study is aimed at providing real-world evidence of the Glycar Pericardial patch. Retrospective data analysis will include collected clinical data from consecutive participants with a minimum of 2 years follow up, meaning from 30 June 2020 and going back in time. The quality of medical history being recorded is believed to be more reliable and complete in the most recent years. Therefore, it was decided to start enrolling consecutive participants in a reverse chronological order.
Study Type
OBSERVATIONAL
Enrollment
50
Glycar Bovine pericardial patch with AldeCaptm Technology (aka SJM with EnCaptm technology)
Red Cross War Memorial Children's Hospital
Cape Town, Rondebosch, South Africa
Reintervention
Incidence of patch related reintervention
Time frame: Within < 30 days post procedure
Mortality
Incidence of patch related mortality
Time frame: Within < 30 days post procedure
Reintervention
Incidence of patch related reintervention
Time frame: Up to 2 years
Mortality
Incidence of patch related mortality
Time frame: Up to 2 years
Infection
Rate of occurrence of Patch infection (such as endocarditis)
Time frame: Up to 2 years
Thrombus formation
Incidence of thrombus formation
Time frame: Within < 30 days post procedure
Unplanned reoperations
The total number of unplanned reoperations required in patients over the FU period which include the repair or alteration of the surgical area around the patch. Patients with planned reoperations at the time of the primary index procedure will not be considered
Time frame: Up to 2 years
Unanticipated AEs
Incidence of patch Unanticipated Adverse Events
Time frame: Up to 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.